Sloan, thanks for asking that question. I'd like to know also about OvaDx. I was hoping that was the test that Mark met with the FDA about in July. But TravO wrote that Mark said that the FDA submission was not for an individual test, more like product line.
Although in the tweets they referred both to "our test" and a "product line"
It's confusing
@arrayit Jul 2
Arrayit CLIA clinical team meets with top brass at the United States Food and Drug Administration FDA to discuss FDA approval of a major product line.
@arrayit Jul 3
Arrayit provides 7/2/18 FDA update: (1) excellent meeting, (2) large attendance by FDA top brass, (3) insightful and instructive, (4) our entire clinical team wishes to thank the agency for their feedback and generosity, and (5) we believe that our test will receive FDA approval.
Market Data 
Markets 
AI
